A股異動丨誠志股份跌逾5% 澄清稱目前暫無猴痘相關領域產品
格隆匯5月24日丨誠志股份跌逾5%,報10.7元,總市值134億元。誠志股份昨日在互動平台回覆稱,公司子公司誠志(美國)生物能量生命科技有限公司以改善膳食健康為使命,利用自有的專利技術,不斷開發出能量管理、耐疲勞、抗缺氧、體重管理、抗衰老、心臟健康等諸多功效的功能性組分,廣泛應用於功能性食品和飲料、膳食補充劑和運動營養與保健產品中。美國公司產品以營養補充類產品為主,如D-核糖、RiaGEV等。目前暫無猴痘相關領域產品。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.